Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 581
Filtrar
2.
Physiol Res ; 68(6): 1021-1026, 2019 12 30.
Artículo en Inglés | MEDLINE | ID: mdl-31647302

RESUMEN

High levels of fructose induce hypertriglyceridemia, characterized by excessive levels of triglyceride-rich lipoproteins such as very low-density lipoprotein (VLDL); however, the underlying mechanisms are poorly understood. The aim of this short communication was to examine hepatic changes in the expression of genes related to cholesterol metabolism in rats with hypertriglyceridemia induced by high-fructose or high-glucose diets. Rats were fed a 65 % (w/w) glucose diet or a 65 % (w/w) fructose diet for 12 days. Serum levels of triglycerides, total cholesterol, and VLDL+LDL-cholesterol, hepatic levels of triglycerides and cholesterol, and ACAT2 expression at the gene and protein levels were significantly higher in the fructose diet group compared to the glucose diet group. The hepatic levels of Abcg5/8 were lower in the fructose group than in the glucose group. Serum high-density lipoprotein (HDL)-cholesterol and hepatic expression levels of Hmgcr, Ldlr, Acat1, Mttp, Apob, and Cyp7a1 did not differ significantly between groups. These findings suggest that high-fructose diet-induced hypertriglyceridemia is associated with increased hepatic ACAT2 expression.


Asunto(s)
Fructosa/efectos adversos , Hipertrigliceridemia/inducido químicamente , Hipertrigliceridemia/metabolismo , Hígado/metabolismo , Esterol O-Aciltransferasa/biosíntesis , Animales , Fructosa/administración & dosificación , Expresión Génica , Hipertrigliceridemia/genética , Hígado/efectos de los fármacos , Masculino , Ratas , Ratas Wistar , Esterol O-Aciltransferasa/genética , Esterol O-Aciltransferasa 2
3.
Blood Cancer J ; 7(4): e559, 2017 04 28.
Artículo en Inglés | MEDLINE | ID: mdl-28452984

RESUMEN

Although tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of chronic myeloid leukemia (CML), the ability of TKIs to eradicate CML remains uncertain and patients must continue TKI therapy for indefinite periods. In this study, we performed whole-exome sequencing to identify somatic mutations in 24 patients with newly diagnosed chronic phase CML who were registered in the JALSG CML212 study. We identified 191 somatic mutations other than the BCR-ABL1 fusion gene (median 8, range 1-17). Age, hemoglobin concentration and white blood cell counts were correlated with the number of mutations. Patients with mutations ⩾6 showed higher rate of achieving major molecular response than those<6 (P=0.0381). Mutations in epigenetic regulator, ASXL1, TET2, TET3, KDM1A and MSH6 were found in 25% of patients. TET2 or TET3, AKT1 and RUNX1 were mutated in one patient each. ASXL1 was mutated within exon 12 in three cases. Mutated genes were significantly enriched with cell signaling and cell division pathways. Furthermore, DNA copy number analysis showed that 2 of 24 patients had uniparental disomy of chromosome 1p or 3q, which disappeared major molecular response was achieved. These mutations may play significant roles in CML pathogenesis in addition to the strong driver mutation BCR-ABL1.


Asunto(s)
Proteínas de Unión al ADN/genética , Dioxigenasas/genética , Histona Demetilasas/genética , Leucemia Mielógena Crónica BCR-ABL Positiva/genética , Proteínas Proto-Oncogénicas/genética , Proteínas Represoras/genética , Factores de Edad , Variaciones en el Número de Copia de ADN/genética , Resistencia a Antineoplásicos/genética , Epigénesis Genética/genética , Femenino , Proteínas de Fusión bcr-abl/genética , Humanos , Leucemia Mielógena Crónica BCR-ABL Positiva/sangre , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Recuento de Leucocitos , Masculino , Mutación , Inhibidores de Proteínas Quinasas/administración & dosificación , Transducción de Señal , Secuenciación del Exoma
4.
Leukemia ; 28(8): 1586-95, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24487413

RESUMEN

To clarify the cooperative roles of recurrently identified mutations and to establish a more precise risk classification system in acute myeloid leukemia (AML), we comprehensively analyzed mutations in 51 genes, as well as cytogenetics and 11 chimeric transcripts, in 197 adult patients with de novo AML who were registered in the Japan Adult Leukemia Study Group AML201 study. We identified a total of 505 mutations in 44 genes, while only five genes, FLT3, NPM1, CEBPA, DNMT3A and KIT, were mutated in more than 10% of the patients. Although several cooperative and exclusive mutation patterns were observed, the accumulated mutation number was higher in cytogenetically normal AML and lower in AML with RUNX1-RUNX1T1 and CBFB-MYH11, indicating a strong potential of these translocations for the initiation of AML. Furthermore, we evaluated the prognostic impacts of each sole mutation and the combinations of mutations and/or cytogenetics, and demonstrated that AML patients could be clearly stratified into five risk groups for overall survival by including the mutation status of DNMT3A, MLL-PTD and TP53 genes in the risk classification system of the European LeukemiaNet. These results indicate that the prognosis of AML could be stratified by the major mutation status in combination with cytogenetics.


Asunto(s)
Leucemia Mieloide Aguda/genética , Mutación , Adolescente , Adulto , Proteínas Potenciadoras de Unión a CCAAT/genética , Citogenética , Supervivencia sin Enfermedad , Humanos , Cariotipo , Leucemia Mieloide Aguda/mortalidad , Persona de Mediana Edad , Nucleofosmina , Pronóstico , Proteínas Proto-Oncogénicas c-kit/genética , Tirosina Quinasa 3 Similar a fms/genética
6.
J Periodontal Res ; 46(5): 568-75, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21615409

RESUMEN

BACKGROUND AND OBJECTIVE: Determination of the interleukin-1 (IL-1) signaling cascades that lead to the production of various inflammatory mediators and catabolic factors may clarify attractive targets for therapeutic intervention for periodontitis. We comprehensively assessed the involvement of MAPKs, activator protein-1 (AP-1) and nuclear factor-κB (NF-κB) in IL-1ß-induced production of interleukin-6 (IL-6), interleukin-8 (IL-8), prostaglandin E(2) (PGE(2) ) and MMP-1 in human periodontal ligament cells. MATERIAL AND METHODS: Human periodontal ligament cells were pretreated with an inhibitor for each of the MAPKs or NF-κB and subsequently treated with IL-1ß. Following treatment, phosphorylation of three types of MAPK (ERK, p38 MAPK and c-Jun N-terminal kinase), IκB kinase (IKK) α/ß/γ and IκB-α, as well as the DNA binding activity of AP-1 and NF-κB and the production of IL-6, IL-8, PGE(2) and MMP-1, were determined by western blotting, a gel mobility shift assay and ELISA, respectively. RESULTS: The three MAPKs, simultaneously activated by IL-1ß, mediated the subsequent DNA binding of AP-1 at various magnitudes, while IKKα/ß/γ, IκB-α and NF-κB were also involved in the IL-1 signaling cascade. Furthermore, IL-1ß stimulated the production of IL-6, IL-8, PGE(2) and MMP-1 via activation of the three MAPKs and NF-κB, because inhibitors of these significantly suppressed the IL-1ß-stimulated production of these factors. CONCLUSION: Our results strongly suggest that MAPK, AP-1 and NF-κB mediate the IL-1ß-stimulated synthesis of IL-6, IL-8, PGE(2) and MMP-1 in human periodontal ligament cells. Therefore, inhibition of activation of MAPK, AP-1 and/or NF-κB may lead to therapeutic effects on progression of periodontitis.


Asunto(s)
Citocinas/biosíntesis , Proteínas Quinasas Activadas por Mitógenos/metabolismo , FN-kappa B/fisiología , Ligamento Periodontal/metabolismo , Factor de Transcripción AP-1/metabolismo , Adolescente , Células Cultivadas , Dinoprostona/biosíntesis , Humanos , Interleucina-1beta/metabolismo , Interleucina-6/biosíntesis , Interleucina-8/biosíntesis , Metaloproteinasa 1 de la Matriz/biosíntesis , Proteínas Quinasas Activadas por Mitógenos/antagonistas & inhibidores , FN-kappa B/antagonistas & inhibidores , Ligamento Periodontal/citología , Transducción de Señal , Adulto Joven
7.
Leukemia ; 23(7): 1329-36, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19369961

RESUMEN

We studied the effect of CMC-544, the calicheamicin-conjugated anti-CD22 monoclonal antibody, used alone and in combination with rituximab, analyzing the quantitative alteration of target molecules, that is, CD20, CD22, CD55 and CD59, in Daudi and Raji cells as well as in cells obtained from patients with B-cell malignancies (BCM). Antibody inducing direct antiproliferative and apoptotic effect, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) were tested separately. In Daudi and Raji cells, the CDC effect of rituximab significantly increased within 12 h following incubation with CMC-544. The levels of CD22 and CD55 were significantly reduced (P<0.001 in both cells) after incubation with CMC-544, but CD20 level remained constant or increased for 12 h. Similar results were obtained in cells from 12 patients with BCM. The antiproliferative and apoptotic effect of CMC-544 were greater than that of rituximab. The ADCC of rituximab was not enhanced by CMC-544. Thus, the combination of CMC-544 and rituximab increased the in vitro cytotoxic effect in BCM cells, and sequential administration for 12 h proceeded by CMC-544 was more effective. The reduction of CD55 and the preservation of CD20 after incubation with CMC-544 support the rationale for the combined use of CMC-544 and rituximab.


Asunto(s)
Anticuerpos Monoclonales/farmacología , Antineoplásicos/farmacología , Linfoma de Células B/inmunología , Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales Humanizados , Citotoxicidad Celular Dependiente de Anticuerpos/efectos de los fármacos , Antineoplásicos/inmunología , Secuencia de Bases , Línea Celular Tumoral , Cartilla de ADN , Citometría de Flujo , Humanos , Inotuzumab Ozogamicina , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Lectina 2 Similar a Ig de Unión al Ácido Siálico/inmunología
8.
Br J Pharmacol ; 152(7): 1021-32, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17618308

RESUMEN

BACKGROUND AND PURPOSE: Both parasympathetic tone and atrial tachycardia (AT) remodelling of ion channels play important roles in atrial fibrillation (AF) pathophysiology. Different muscarinic cholinergic receptor (mAChR) subtypes (M2, M3, M4) in atrial cardiomyocytes are coupled to distinct K+-currents (called IKM2, IKM3, IKM4, respectively). Pulmonary veins (PVs) are important in AF and differential cholinergic current responses are a potential underlying mechanism. This study investigated AT-induced remodelling of mAChR subtypes and K+-currents in left-atrial (LA) and PV cardiomyocytes. EXPERIMENTAL APPROACH: Receptor expression was assayed by western blot. IKM2, IKM3 and IKM4 were recorded with whole-cell patch-clamp in LA and PV cardiomyocytes of nonpaced control dogs and dogs after 7 days of AT-pacing (400 bpm). KEY RESULTS: Current densities of IKM2, IKM3 and IKM4 were significantly reduced by AT-pacing in LA and PV cardiomyocytes. PV cardiomyocyte current-voltage relations were similar to LA for all three cholinergic currents, both in control and AT remodelling. Membrane-protein expression levels corresponding to M2, M3 and M4 subtypes were decreased significantly (by about 50%) after AT pacing. Agonist concentration-response relations for all three currents were unaffected by AT pacing. CONCLUSIONS AND IMPLICATIONS: AT downregulated all three mAChR-coupled K+-current subtypes, along with corresponding mAChR protein expression. These changes in cholinergic receptor-coupled function may play a role in AF pathophysiology. Cholinergic receptor-coupled K+-currents in PV cardiomyocytes were similar to those in LA under control and AT-pacing conditions, suggesting that differential cholinergic current properties do not explain the role of PVs in AF.


Asunto(s)
Atrios Cardíacos/metabolismo , Miocitos Cardíacos/metabolismo , Canales de Potasio de Rectificación Interna/metabolismo , Venas Pulmonares/metabolismo , Receptores Muscarínicos/metabolismo , Taquicardia Atrial Ectópica/metabolismo , Animales , Fibrilación Atrial/metabolismo , Fibrilación Atrial/fisiopatología , Western Blotting , Estimulación Cardíaca Artificial , Células Cultivadas , Modelos Animales de Enfermedad , Perros , Regulación hacia Abajo , Técnicas Electrofisiológicas Cardíacas , Potenciales Evocados , Atrios Cardíacos/patología , Miocitos Cardíacos/patología , Técnicas de Placa-Clamp , Venas Pulmonares/patología , Receptores Muscarínicos/biosíntesis , Taquicardia Atrial Ectópica/fisiopatología , Factores de Tiempo
10.
Water Sci Technol ; 53(2): 155-61, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16594334

RESUMEN

Chitosan, acetylate of chitin, is a biodegradable cationic polymer. The objective of this study is to assess the applicability of chitosan as an on-site treatment agent of turbid water caused by river construction works and other diffused pollutions. The results of jar-tests indicate that floc of chitosan is much larger than that of aluminium sulfate, and turbidity treated by chitosan under moving water conditions is much lower than that of aluminium sulfate. Chitosan is applied to Imou River in Yamaguchi prefecture, where river construction work is going on. St.1 is located just below the construction work, St.2 is located about 250 m downstream from St.1, and St.3 is located about 350 m downstream from St.2. Initial turbidity of each station is 1,100, 937 and 313 NTU, respectively. By applying chitosan at St.1, turbidity of each station is drastically reduced to 1,100, 12 and 0 NTU. Chitosan could be helpful to reduce problems caused by turbidity in rivers.


Asunto(s)
Quitosano/farmacología , Polímeros/química , Purificación del Agua/instrumentación , Purificación del Agua/métodos , Compuestos de Alumbre/farmacología , Biodegradación Ambiental , Cationes , Monitoreo del Ambiente , Concentración de Iones de Hidrógeno , Ríos , Eliminación de Residuos Líquidos , Agua , Contaminantes del Agua , Contaminación del Agua , Abastecimiento de Agua
11.
Handb Exp Pharmacol ; (171): 235-66, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16610347

RESUMEN

Drugs that suppress beta-adrenergic signaling by competitively inhibiting agonist binding to beta-adrenergic receptors ("beta-blockers") have important antiarrhythmic properties. They differ from most other antiarrhythmic agents by not directly modifying ion channel function; rather, they prevent the arrhythmia-promoting actions of beta-adrenergic stimulation. beta-Blockers are particularly useful in preventing sudden death due to ventricular tachyarrhythmias associated with acute myocardial ischemia, congenital long QT syndrome, and congestive heart failure. They are also quite valuable in controlling the ventricular rate in patients with atrial fibrillation. This chapter reviews the properties of beta-adrenoceptor signaling, the basic mechanisms of cardiac arrhythmias on which beta-blockers act, the ion channel mediators of beta-adrenergic responses, the evidence for clinical antiarrhythmic indications for beta-blocker therapy and the specific pharmacodynamic and pharmacokinetic properties of beta-blockers that differentiate the various agents of this class.


Asunto(s)
Antagonistas Adrenérgicos beta/farmacología , Antiarrítmicos/farmacología , Potenciales de Acción/efectos de los fármacos , Antagonistas Adrenérgicos beta/farmacocinética , Antagonistas Adrenérgicos beta/uso terapéutico , Animales , Arritmias Cardíacas/tratamiento farmacológico , Arritmias Cardíacas/etiología , Canales de Calcio Tipo L/efectos de los fármacos , Canales de Calcio Tipo L/fisiología , Canales de Cloruro/efectos de los fármacos , Canales de Cloruro/fisiología , Corazón/fisiología , Humanos , Canales de Potasio/efectos de los fármacos , Canales de Potasio/fisiología , Receptores Adrenérgicos beta 1/fisiología , Receptores Adrenérgicos beta 2/fisiología , Intercambiador de Sodio-Calcio/efectos de los fármacos , Intercambiador de Sodio-Calcio/fisiología
12.
Leukemia ; 19(8): 1306-11, 2005 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15920495

RESUMEN

Acute promyelocytic leukemia (APL) cells express a considerable level of CD33, which is a target of gemtuzumab ozogamicin (GO), and a significantly lower level of P-glycoprotein (P-gp). In this study, we examined whether GO was effective on all-trans retinoic acid (ATRA)- or arsenic trioxide (ATO)-resistant APL cells. Cells used were an APL cell line in which P-gp was undetectable (NB4), ATRA-resistant NB4 (NB4/RA), NB4 and NB4/RA that had been transfected with MDR-1 cDNA (NB4/MDR and NB4/RA/MDR, respectively), ATO-resistant NB4 (NB4/As) and blast cells from eight patients with clinically ATRA-resistant APL including two patients with ATRA- and ATO-resistant APL. The efficacy of GO was analyzed by (3)H-thymidine incorporation, the dye exclusion test and cell cycle distribution. GO suppressed the growth of NB4, NB4/RA and NB4/As cells in a dose-dependent manner. GO increased the percentage of hypodiploid cells significantly in NB4, NB4/RA and NB4/As cells, and by a limited degree in NB4/MDR and NB4/RA/MDR cells. Similar results were obtained using blast cells from the patients with APL. GO is effective against ATRA- or ATO-resistant APL cells that do not express P-gp, and the mechanism of resistance to GO is not related to the mechanism of resistance to ATRA or ATO in APL cells. Leukemia (2005) 19, 1306-1311. doi:10.1038/sj.leu.2403807; published online 26 May 2005.


Asunto(s)
Aminoglicósidos/farmacología , Anticuerpos Monoclonales/farmacología , Resistencia a Antineoplásicos , Leucemia Promielocítica Aguda/patología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/análisis , Anticuerpos Monoclonales Humanizados , Trióxido de Arsénico , Arsenicales/farmacología , Ciclo Celular , Proliferación Celular/efectos de los fármacos , Gemtuzumab , Humanos , Leucemia Promielocítica Aguda/tratamiento farmacológico , Óxidos/farmacología , Resultado del Tratamiento , Tretinoina/farmacología , Células Tumorales Cultivadas
14.
Gene Ther ; 11(16): 1273-82, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15175640

RESUMEN

In-stent restenosis results exclusively from neointimal hyperplasia due to mechanical injury and a foreign body response to the prosthesis. Inflammation mediated by monocyte chemoattractant protein-1 (MCP-1) might therefore underlie in-stent restenosis. We recently devised a new strategy for anti-MCP-1 gene therapy by transfecting an N-terminal deletion mutant of the MCP-1 gene into skeletal muscles. We used this strategy to investigate the role of MCP-1 in experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys. Transfection of the mutant MCP-1 gene suppressed monocyte infiltration/activation in the stented arterial wall and markedly reduced the development of neointimal hyperplasia. This strategy also suppressed local expression of MCP-1 and inflammatory cytokines. Therefore, inhibition of MCP-1-mediated inflammation is effective in reducing experimental in-stent restenosis. This strategy might be a useful form of gene therapy against human in-stent restenosis.


Asunto(s)
Quimiocina CCL2/genética , Factores Quimiotácticos/genética , Terapia Genética/métodos , Stents , Animales , Formación de Anticuerpos , Quimiocinas/genética , Reestenosis Coronaria/prevención & control , Citocinas/genética , Expresión Génica/genética , Hiperplasia , Macaca fascicularis , Masculino , Músculo Esquelético , Reacción en Cadena de la Polimerasa/métodos , Falla de Prótesis , Conejos , Recombinación Genética , Transfección
15.
Mod Pathol ; 17(5): 503-11, 2004 May.
Artículo en Inglés | MEDLINE | ID: mdl-15001992

RESUMEN

There are currently no universally accepted indications and criteria for additional surgical resection of the colorectum after endoscopic resection of the submucosal invasive cancer. The purpose of the present study is to establish accurate indications and criteria for additional surgical resection of the colorectum, based on the prediction of lymph node metastasis, after endoscopic resection of the submucosal invasive cancer. We investigated 140 submucosal invasive colorectal cancers and analyzed the pathologic factors of lymph node metastasis. The tumors were evaluated for pathologic factors in the invasive area of the submucosal carcinoma and were compared between the cases with lymph node metastasis and those without lymph node metastasis. Lymph node metastasis was observed in 13 cases (9%). Univariate logistic regression analysis showed that the depth of invasion, cribriform-type structural atypia, absence of lymphoid infiltration, lymphatic permeation, and venous permeation were statistically significant as risk factors for lymph node metastasis. Multivariate logistic regression analysis showed that the important risk factors included, in decreasing order, lymphatic permeation, absence of lymphoid infiltration, cribriform-type structural atypia, venous permeation, and depth of invasion. Submucosal invasion of 2 mm or more, and/or, depth of lymphatic permeation of 2 mm or more are risk factors for lymph node metastasis. The pathologic criteria based on our results for additional colectomy enables greater accuracy selection of patients who will undergo further surgical treatment after endoscopic resection.


Asunto(s)
Neoplasias del Colon/patología , Mucosa Intestinal/patología , Ganglios Linfáticos/patología , Metástasis Linfática/diagnóstico , Algoritmos , Neoplasias del Colon/cirugía , Humanos , Modelos Logísticos , Análisis Multivariante , Invasividad Neoplásica , Factores de Riesgo , Sensibilidad y Especificidad
16.
Gene Ther ; 11(2): 126-32, 2004 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-14712296

RESUMEN

Early growth response factor-1 (Egr-1) is a transcription factor that is rapidly activated after vascular injury and thus might contribute to vascular proliferation and inflammation. We hypothesized that Egr-1 might therefore be a therapeutic target against restenosis. Hypercholesterolemic rabbits were intraluminally administered synthetic DNA as a 'decoy' against Egr-1 immediately after carotid artery balloon injury. Efficient transfection was confirmed by the delivery of a fluorescence-labeled decoy. Gel mobility-shift assay showed increased Egr-1 activity after balloon injury and its prevention by Egr-1 decoy transfection in vivo. Egr-1 decoy transfection attenuated early inflammation and proliferation and later neointimal hyperplasia. In addition, Egr-1 decoy transfection reduced gene expression and protein production of Egr-1-dependent genes such as platelet-derived growth factor-B, transforming growth factor-beta1, and monocyte chemoattractant protein-1. The Egr-1 pathway has an essential role in the pathogenesis of neointimal hyperplasia after balloon injury in hypercholesterolemic rabbits. This decoy strategy is a potential practical form of therapy for human restenosis.


Asunto(s)
Angioplastia de Balón/efectos adversos , Traumatismos de las Arterias Carótidas/patología , Estenosis Carotídea/prevención & control , Proteínas de Unión al ADN/genética , ADN/administración & dosificación , Terapia Genética/métodos , Factores de Transcripción/genética , Animales , Estenosis Carotídea/patología , Ensayo de Cambio de Movilidad Electroforética , Expresión Génica , Hipercolesterolemia/patología , Hiperplasia , Modelos Animales , Conejos , Transfección/métodos , Túnica Íntima/patología
18.
J Clin Pharm Ther ; 28(6): 505-12, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14651675

RESUMEN

OBJECTIVE: The incidence of and risk factors for delayed adverse events (DAEs) that appear from 1 h to 7 days after injection of radiographic contrast media were investigated in patients who had undergone coronary angiography (CAG). METHODS: DAEs were monitored by questionnaire in 155 patients who received iomeprol. Isosorbide dinitrate was injected in every case. Risk factors for DAEs were analysed by a logistic regression model. RESULTS: Of 118 patients who returned questionnaires, 54 complained of DAEs, although no severe or fatal reactions occurred. Erythema, rash and nausea were frequent events. Female gender, total dose of isosorbide dinitrate <2 mg, and execution of acetylcholine provocation test were found to be the major risk factors, and the incidence of DAEs increased as the number of risk factors increased. CONCLUSION: Care should be taken when CAG is performed on female patients who undergo acetylcholine provocation tests and receive low-dose nitric oxide donor injections.


Asunto(s)
Medios de Contraste/efectos adversos , Angiografía Coronaria , Yopamidol/análogos & derivados , Yopamidol/efectos adversos , Anciano , Femenino , Humanos , Incidencia , Dinitrato de Isosorbide/uso terapéutico , Modelos Logísticos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Factores de Riesgo , Encuestas y Cuestionarios , Factores de Tiempo , Vasodilatadores/uso terapéutico
20.
Eur J Clin Nutr ; 56(7): 629-37, 2002 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12080402

RESUMEN

OBJECTIVE: To determine the serum cholesterol, apolipoproteins and LDL oxidizability in young Japanese women and men during walnut consumption and to evaluate its active principle. DESIGN: Experimental study with a randomized design. SUBJECTS: Twenty healthy women and 20 healthy men. INTERVENTIONS: Subjects were randomly assigned to consume each of two mixed natural diets for 4 weeks in a cross-over design. Reference and walnut diets were designed and the walnut diet had 12.5% of the energy derived from walnuts (44-58 g/day). RESULTS: The total cholesterol and serum apolipoprotein B concentrations, and the ratio of LDL cholesterol to HDL cholesterol was significantly lowered in women and men when fed on the walnut diet, than when on the reference diet (P

Asunto(s)
Apolipoproteínas B/sangre , Colesterol/sangre , Nueces , Adulto , Ésteres del Colesterol/química , HDL-Colesterol/sangre , LDL-Colesterol/sangre , LDL-Colesterol/metabolismo , Estudios Cruzados , Femenino , Humanos , Japón , Ácido Linoleico/metabolismo , Masculino , Oxidación-Reducción , Factores Sexuales , Método Simple Ciego , Triglicéridos/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA